Zydus Wellness Q1 profit falls 7% despite 67% revenue growth; shares drop over 3%

Zydus Wellness reported Q1 consolidated net profit of Rs 119 crore, down from Rs 128 crore a year earlier, while revenue rose 66.9% to Rs 1,437 crore. EBITDA increased 55.3% to Rs 242 crore, but margin narrowed to 16.8% from 18.1%.

— Source publishedTue, 4 Aug, 2026, 12:45 IST·First seen Tue, 4 Aug, 2026, 13:13 IST·Source NDTV Profit

What happened

Zydus Wellness reported strong Q1 revenue and EBITDA growth, but net profit fell 7% and EBITDA margin contracted. Its shares dropped over 3%, while the company

Key facts

  • Q1 consolidated net profit: Rs 119 crore, down 7% YoY from Rs 128 crore
  • Revenue from operations: Rs 1,437 crore, up 66.9% YoY from Rs 861 crore
  • EBITDA: Rs 242 crore, up 55.3% YoY from Rs 156 crore
  • EBITDA margin: 16.8%, versus 18.1% a year earlier
  • Share price: Rs 538.95, down over 3% from previous close of Rs 559.85
  • One-month stock decline: nearly 10%
  • One-year stock gain: 31.2%
  • Market capitalisation: Rs 17,153.6 crore

Why this matters

The results underline the appeal of growth-accretive FMCG expansion, while also showing that integration, input costs and product mix must be managed to protect profitability.

What to watch

  • Organic volume growth versus reported revenue growth in the next quarterly update.
  • EBITDA margin trajectory relative to the 16.8% Q1 level and the 18.1% prior-year benchmark.
  • Management guidance on input costs, advertising and promotion spend, and integration expenses.
  • Gross-margin movement, indicating whether pricing and product mix are offsetting cost inflation.
  • Repeat performance in core brands and rural versus urban demand trends.
  • Any downgrade to FY profit estimates or additional share-price weakness after analyst calls.
  • Investors will seek management commentary on whether the 66.9% revenue increase is organic, acquisition-related, or driven by channel inventory and pricing.
  • The company is likely to prioritize cost control, procurement savings and selective price/mix actions to defend EBITDA margin.
  • Brand and distribution investments may be calibrated more tightly, particularly if post-acquisition integration or premium-category expansion is weighing on profitability.
  • Analysts may revise FY earnings expectations downward unless management provides a credible timeline for margin normalization.